Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Taiwan Biomateiral Co's EV-to-EBIT or its related term are showing as below:
ROCO:6649'
s EV-to-EBIT Range Over the Past 10 Years
Min: -939.61 Med: -14.84 Max: 370.74
Current: 38.56
During the past 12 years, the highest EV-to-EBIT of Taiwan Biomateiral Co was 370.74. The lowest was -939.61. And the median was -14.84.
ROCO:6649's EV-to-EBIT is ranked worse than 79.05% of 482
companies
in the Medical Devices & Instruments industry
Industry Median: 18.035
vs ROCO:6649: 38.56
Taiwan Biomateiral Co (ROCO:6649) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Taiwan Biomateiral Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,401.3 Mil.
Taiwan Biomateiral Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$33.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Taiwan Biomateiral Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Biomateiral Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Taiwan Biomateiral Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Taiwan Biomateiral Co's EV-to-EBIT falls into.
Taiwan Biomateiral Co's current Enterprise Value is NT$1,306.8 Mil.
Taiwan Biomateiral Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$33.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Biomateiral Co (ROCO:6649) has a EV-to-EBIT of 38.56 as of Sep. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiwan Biomateiral Co and its competitors. According to the industry distribution chart, Taiwan Biomateiral Co ranks #381 out of 482 companies in the Medical Devices & Instruments industry, placing it in the top 79%.
Is Taiwan Biomateiral Co's EV-to-EBIT too high?
Taiwan Biomateiral Co's current EV-to-EBIT is 38.56. The Medical Devices & Instruments industry median EV-to-EBIT is 18.04. Taiwan Biomateiral Co's value of 38.56 is 113.8% above this industry median. Based on the distribution chart, Taiwan Biomateiral Co ranks #381 out of 482 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Taiwan Biomateiral Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Biomateiral Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Taiwan Biomateiral Co ranks #381 out of 482 companies for EV-to-EBIT. This places Taiwan Biomateiral Co in the lower half of its industry. The industry median EV-to-EBIT is 18.04. Taiwan Biomateiral Co's value of 38.56 is 113.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.04, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Biomateiral Co's current EV-to-EBIT of 38.56 is 113.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Taiwan Biomateiral Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Biomateiral Co's current EV-to-EBIT is 38.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Biomateiral Co stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Biomateiral Co (ROCO:6649) is currently considered Possible Value Trap. The stock's GF Value™ is NT$59.02, compared to a current price of NT$35.45 — trading 39.9% below its estimated fair value. The current EV-to-EBIT is 38.56 and 113.8% above the Medical Devices & Instruments industry median of 18.04. Taiwan Biomateiral Co's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Taiwan Biomateiral Co (ROCO:6649), the current EV-to-EBIT is 38.56 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Biomateiral Co (ROCO:6649) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Biomateiral Co stock appears to be undervalued.
The current stock price of NT$35.45 is trading 39.9% below its estimated GF Value™ of NT$59.02.
GuruFocus considers Taiwan Biomateiral Co to be Possible Value Trap.
Key valuation signals for ROCO:6649:
EV-to-EBIT: 38.56
GF Value™: NT$59.02 vs. price of NT$35.45 (39.9% below fair value)
Industry Position: 113.8% above the Medical Devices & Instruments median (#381 of 482)
No single metric tells the full story. See the ROCO:6649 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Biomateiral Co Ltd is an applied technology Research and Development Institute in Taiwan. It is engaged in the research and development and sales of implantable medical devices. The company's products include Foamagen, stroke interventional treatment devices.
80GF Score
Get the complete analysis for ROCO:6649
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6649 has been successfully added to your 
